Lupin MD on a biosimilars play fused around Japan 'anchor'

Lupin may have been slow off the block in the biosimilars space in emerging markets compared with some of its Indian peers, but the Mumbai-based firm is hoping that a strategy centred around its "anchor market" Japan may more than compensate as well as propelling its entry into the US and Europe.